Skip to main content

Table 1 Description of HRT Trials.

From: Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

Study Length months Type of Oestrogen Progestin+ Addition of calcium* Study Population Outcome measure Age (SD/range)
Alexandersen 1999 [12] 22 50-ug transdermal estradiol +* Healthy postmenopausal women with low BMD BMD 65 (2.2)
Delmas 2000 [5] 24 Oral 1 mg estradiol +* Healthy >1 year postmenopausal women with normal BMD. BMD 58 (5)
Gallagher 2001 [14] 36 Oral 0.625 mg conjugated estrogens +* Elderly women with normal bone density BMD 72(± 4)
Cauley 2001 [4] 49 Oral 0.625 conjugated estrogen + Women with established coronary disease >5 years post menopause MI or CHD 67
Herrington 2000 [6] 38 Oral 0.625 conjugated estrogen + Women with coronary arterial disease (CAD) CAD Progression 66 (7.0)
Ishida 2001 [15] 12 Oral 0.625 conjugated estrogen. + Women with established osteoporosis. BMD 70 (7.6)
Lindsay 1990 [13] 24 Oral 0.625 mg conjugated estrogen +* Postmenopausal women with 1+ vertebral fracture & low BMD BMD 48 (1.0)
Lufkin 1992 [1] 12 Transdermal 0.1 mg 17β-estradiol + Postmenopausal white women with documented osteoporosis BMD 64.8 (54.9 to 71.3)
Mosekilde 2000 [7] 60 Oral 1 mg or 2 mg estradiol + Healthy women 3–24 months post menopause Fractures 50 (2.8)
PEPI 1996 [8] 36 Oral 0.625 mg conjugated estrogen + Healthy women 1–10 years post menopause normal BMD BMD 56 (0.3)
Ravn 1999 [9] 48 Oral 0.625 conjugated estrogen or 2 mg estradiol + Healthy 6+ months postmenopausal women under 60 years BMD 55
Recker 1999 [10] 42 0.3 mg conjugated estrogen +* Healthy women average BMD t-score-3.5 at femur BMD 73 (5.0)
Wimalawansa 1998 [11] 48 Oral 0.625 conjugated estrogen +* Women with established osteoporosis (1+vertebral fracture) BMD 65 (0.9)